Clarke PA - Search Results

1

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.

Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, Czodrowski P, Musil D, Schwarz D, Ortiz-Ruiz MJ, Schneider R, Thai C, Valenti M, de Haven Brandon A, Burke R, Workman P, Dale T, Wienke D, Clarke PA, Esdar C, Raynaud FI, Eccles SA, Rohdich F, Blagg J. Mallinger A, et al. Among authors: clarke pa. J Med Chem. 2016 Feb 11;59(3):1078-101. doi: 10.1021/acs.jmedchem.5b01685. Epub 2016 Jan 21. J Med Chem. 2016. PMID: 26796641 Free PMC article.

2

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: clarke pa. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

3

Innovative cancer drug targets: genomics, transcriptomics and clinomics.

Workman P, Clarke PA. Workman P, et al. Among authors: clarke pa. Expert Opin Pharmacother. 2001 Jun;2(6):911-5. doi: 10.1517/14656566.2.6.911. Expert Opin Pharmacother. 2001. PMID: 11585007 No abstract available.

4

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR. Kelland LR, et al. Among authors: clarke pa. Clin Cancer Res. 2001 Nov;7(11):3544-50. Clin Cancer Res. 2001. PMID: 11705875

5

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

Clarke PA, te Poele R, Wooster R, Workman P. Clarke PA, et al. Biochem Pharmacol. 2001 Nov 15;62(10):1311-36. doi: 10.1016/s0006-2952(01)00785-7. Biochem Pharmacol. 2001. PMID: 11709192 Review.

6

Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective.

Maloney A, Clarke PA, Workman P. Maloney A, et al. Among authors: clarke pa. Curr Cancer Drug Targets. 2003 Oct;3(5):331-41. doi: 10.2174/1568009033481822. Curr Cancer Drug Targets. 2003. PMID: 14529385 Review.

7

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Clarke PA, George ML, Easdale S, Cunningham D, Swift RI, Hill ME, Tait DM, Workman P. Clarke PA, et al. Cancer Res. 2003 Oct 15;63(20):6855-63. Cancer Res. 2003. PMID: 14583483

8

Gene expression microarray technologies in the development of new therapeutic agents.

Clarke PA, te Poele R, Workman P. Clarke PA, et al. Eur J Cancer. 2004 Nov;40(17):2560-91. doi: 10.1016/j.ejca.2004.07.024. Eur J Cancer. 2004. PMID: 15541959 Review.

9

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

Hardcastle A, Boxall K, Richards J, Tomlin P, Sharp S, Clarke P, Workman P, Aherne W. Hardcastle A, et al. Assay Drug Dev Technol. 2005 Jun;3(3):273-85. doi: 10.1089/adt.2005.3.273. Assay Drug Dev Technol. 2005. PMID: 15971989

10

Drugging the PI3 kinome.

Workman P, Clarke PA, Guillard S, Raynaud FI. Workman P, et al. Among authors: clarke pa. Nat Biotechnol. 2006 Jul;24(7):794-6. doi: 10.1038/nbt0706-794. Nat Biotechnol. 2006. PMID: 16841064 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page